Back to Search
Start Over
Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
- Source :
-
Chinese clinical oncology [Chin Clin Oncol] 2024 Feb; Vol. 13 (1), pp. 14. Date of Electronic Publication: 2023 Oct 09. - Publication Year :
- 2024
- Subjects :
- Male
Humans
Docetaxel pharmacology
Docetaxel therapeutic use
Androgen Antagonists pharmacology
Androgen Antagonists therapeutic use
Androgens therapeutic use
Standard of Care
Antineoplastic Combined Chemotherapy Protocols pharmacology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Prostatic Neoplasms drug therapy
Prostatic Neoplasms pathology
Prostatic Neoplasms, Castration-Resistant drug therapy
Pyrazoles
Subjects
Details
- Language :
- English
- ISSN :
- 2304-3873
- Volume :
- 13
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Chinese clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 37817509
- Full Text :
- https://doi.org/10.21037/cco-23-66